This is the second time in a matter of weeks the FDA has approved an RDN system for uncontrolled hypertension. The SCAI issued a statement about this trend, calling it a “game-changer for both interventional cardiology and the treatment of hypertension."

While the therapy has been successfully tested on animals in the past, this study represents the first time it has been used on humans.

Researchers evaluated two techniques for predicting PPM after TAVR, comparing them to how cardiologists typically check for PPM in day-to-day practice. 

“Marijuana use isn’t without its health concerns, and our study provides more data linking its use to cardiovascular conditions," one researcher said. 

ChatGPT may not be quite ready to help prepare trainees for their next echocardiography exam—but it does show promise. 

Jamie Bourque, MD, spoke to Cardiovascular Business about the growing number of ways FDG-PET scans are being used in cardiology. This includes evaluating inflammation, tracking EP device infections and much more. 

While TAVR is safe for minimally symptomatic patients, questions remain about whether or not it is actually needed. A new analysis in JACC: Cardiovascular Interventions examines this topic in detail.

Novo Nordisk shared initial results from the SELECT trial back in August, but now the full analysis—which includes data from more than 17,000 patients—has been published in The New England Journal of Medicine.